Outcry as cost watchdog bars Bayer’s liver cancer drug from NHS
The National Institute for Health and Clinical Excellence has sparked widespread outrage with a decision that would bar patients with liver cancer from access to Bayer’s Nexavar on the National Health Service.
Read More




